NCT01054404

Brief Summary

Increased brain bulk may be problematic during brain surgery for tumors because it may limit surgical exposure and access to the surgical site. Mannitol, an osmotic diuretic, is commonly given to alleviate brain bulk, and sometimes furosemide in a small dose is added if mannitol alone is insufficient. It is unclear if adding this furosemide truly helps to diminish brain bulk, and it is possible that furosemide may cause too much diuresis, leading to dehydration and its side effects (e.g., low blood pressure). Our purpose is to investigate what the effects of furosemide are in the setting of brain surgery for tumors, specifically with regards to decreasing brain bulk and/or causing dehydration. Study Hypothesis: The addition of furosemide to mannitol will result in improved brain relaxation in human subjects undergoing craniotomy for brain tumor resection than that seen with mannitol alone. However, the combination of mannitol and furosemide will also lead to more significant intravascular volume depletion than that seen with mannitol alone.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 20, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 22, 2010

Completed
10 days until next milestone

Study Start

First participant enrolled

February 1, 2010

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

August 2, 2013

Completed
Last Updated

August 2, 2013

Status Verified

June 1, 2013

Enrollment Period

2.1 years

First QC Date

January 20, 2010

Results QC Date

May 8, 2013

Last Update Submit

June 27, 2013

Conditions

Keywords

Brain SwellingBrain EdemaDehydration

Outcome Measures

Primary Outcomes (1)

  • Acceptable vs. Unacceptable Brain Relaxation at Dural Opening

    Rating of brain relaxation will be on a 4-point scale: 0 = brain very relaxed under dura, acceptable 1. = brain adequately relaxed under dura, acceptable 2. = brain slightly tense under dura, acceptable 3. = brain very tense under bulging dura, unacceptable

    just prior to dural opening for each subject

Study Arms (2)

Furosemide

ACTIVE COMPARATOR

Furosemide 0.3 mg/kg

Drug: Furosemide

Placebo

PLACEBO COMPARATOR

Up to 5 mL saline

Drug: Placebo

Interventions

Furosemide 0.3 mg/kg

Also known as: Lasix
Furosemide

Placebo (up to 5mL)

Also known as: Saline
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA PS I-III
  • Age 18 or older
  • Presenting for elective resection of primary or metastatic supratentorial brain tumor(s)

You may not qualify if:

  • ASA PS IV or V
  • Age less than 18
  • Emergency surgery due to severely elevated ICP/impending brainstem herniation
  • Concurrent use of diuretics for any indication
  • Infratentorial/posterior fossa/cerebellar tumor resection
  • Moderate/severe cardiac disease with limitation in contractility as measured by preoperative echocardiogram (EF \< 30%)
  • Severe pulmonary hypertension as measured and/or observed by preoperative studies
  • Preoperative use of steroids (within 6 months, including those on standing doses)
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University

Chicago, Illinois, 60611, United States

Location

Related Publications (5)

  • Thenuwara K, Todd MM, Brian JE Jr. Effect of mannitol and furosemide on plasma osmolality and brain water. Anesthesiology. 2002 Feb;96(2):416-21. doi: 10.1097/00000542-200202000-00029.

    PMID: 11818776BACKGROUND
  • Todd MM, Cutkomp J, Brian JE. Influence of mannitol and furosemide, alone and in combination, on brain water content after fluid percussion injury. Anesthesiology. 2006 Dec;105(6):1176-81. doi: 10.1097/00000542-200612000-00017.

    PMID: 17122580BACKGROUND
  • Rudehill A, Lagerkranser M, Lindquist C, Gordon E. Effects of mannitol on blood volume and central hemodynamics in patients undergoing cerebral aneurysm surgery. Anesth Analg. 1983 Oct;62(10):875-80.

    PMID: 6412595BACKGROUND
  • Todd MM, Warner DS, Sokoll MD, Maktabi MA, Hindman BJ, Scamman FL, Kirschner J. A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. Anesthesiology. 1993 Jun;78(6):1005-20. doi: 10.1097/00000542-199306000-00002.

    PMID: 8512094BACKGROUND
  • Rozet I, Tontisirin N, Muangman S, Vavilala MS, Souter MJ, Lee LA, Kincaid MS, Britz GW, Lam AM. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology. 2007 Nov;107(5):697-704. doi: 10.1097/01.anes.0000286980.92759.94.

    PMID: 18073543BACKGROUND

MeSH Terms

Conditions

Brain EdemaDehydration

Interventions

FurosemideSodium Chloride

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesWater-Electrolyte ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

SulfanilamidesSulfonamidesAmidesOrganic ChemicalsAniline CompoundsAminesSulfonesSulfur CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Limitations and Caveats

Recruitment was stopped at 23 subjects because of concern that the administration of furosemide was producing such a large diuresis that clinically significant and potentially unsafe hypovolemia and electrolyte abnormalities were developing.

Results Point of Contact

Title
Dr. John F. Bebawy, Assistant Professor of Anesthesiology & Neurological Surgery
Organization
Northwestern University

Study Officials

  • John F Bebawy, MD

    Northwestern University

    PRINCIPAL INVESTIGATOR
  • Dhanesh K Gupta, MD

    Northwestern University

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Anesthesiology & Neurological Surgery

Study Record Dates

First Submitted

January 20, 2010

First Posted

January 22, 2010

Study Start

February 1, 2010

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

August 2, 2013

Results First Posted

August 2, 2013

Record last verified: 2013-06

Locations